Skip to main content

Advertisement

SpringerLink
Log in

Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

This study is to evaluate the association of polymorphisms of glutathione S-transferase P1 (GSTP1), copper-transporting P-type adenosine triphosphatase A (ATP7A) and X-ray repair cross-complementing group 1 (XRCC1) with the efficacy and toxicity of cisplatin-based treatment in advanced non-small cell lung cancer (NSCLC) patients.

Materials and methods

The outcomes of 97 advanced non-small cell lung cancer patients treated with cisplatin-based chemotherapy were estimated. GSTP1, ATP7A, and XRCC1 genetic polymorphisms were determined via polymerase chain reaction of restriction fragment length polymorphism (PCR–RFLP) and DNA sequencing. Association of the polymorphisms with the efficacy and toxicity of cisplatin was analyzed, respectively.

Results

Significant associations were observed between GSTP1 A313G and response rate (RR) (p = 0.027), disease control rate (DCR) (p = 0.019), and progression-free survival (PFS) (p = 0.044), respectively. Patients with AG and GG of GSTP1 have notably lower risk of anemia (p = 0.046). XRCC1 A1196G was associated with the incidence of lymphopenia (p = 0.024) and diarrhea (p = 0.020). ATP7A C2299G was not related with RR, DCR, PFS, and the risk of toxicity.

Conclusions

Advanced NSCLC patients with AA genotype of GSTP1 would obtain better curative effect followed with more risk of anemia when treated by cisplatin-based chemotherapy. ATP7A C2299G does not impact the efficacy and toxicity of cisplatin-based chemotherapy. XRCC1 1196A allele could predict the incidence of lymphopenia and diarrhea.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.

    Article  PubMed  Google Scholar 

  2. Zhou F, Yu Z, Jiang T, Lv H, Yao R, Liang J. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Med Wkly. 2011;141:w13275.

    PubMed  Google Scholar 

  3. Hirano T, Kato H, Maeda M, Gong Y, Shou Y, Nakamura M, et al. Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker. Int J Cancer. 2005;117(3):460–8.

    Article  CAS  PubMed  Google Scholar 

  4. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307–20.

    Article  CAS  PubMed  Google Scholar 

  5. Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008;7(10):3247–55.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83.

    Article  CAS  PubMed  Google Scholar 

  7. Zhu G, Lippard SJ. Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin–DNA interstrand cross-links. Biochemistry. 2009;48(22):4916–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Schneider J, Classen V, Bernges U, Philipp M. XRCC1 polymorphism and lung cancer risk in relation to tobacco smoking. Int J Mol Med. 2005;16(4):709–16.

    CAS  PubMed  Google Scholar 

  9. Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol. 2010;33(5):489–94.

    Article  CAS  PubMed  Google Scholar 

  10. Wheeler HE, Gamazon ER, Stark AL, O’Donnell PH, Gorsic LK, Huang RS, et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenom J. 2013;13(1):35–43.

    Article  CAS  Google Scholar 

  11. Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 2013;108(8):1695–703.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Booton R, Ward T, Heighway J, Ashcroft L, Morris J, Thatcher N. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol. 2006;1(7):679–83.

    Article  PubMed  Google Scholar 

  13. Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genom. 2009;19(8):613–25.

    Article  CAS  Google Scholar 

  14. Chen S, Huo X, Lin Y, Ban H, Li W, Zhang B, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health. 2010;213(2):140–5.

    Article  CAS  PubMed  Google Scholar 

  15. Oguri T, Fujiwara Y, Katoh O, Daga H, Ishikawa N, Fujitaka K, et al. Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer. Cancer Lett. 2000;156(1):93–9.

    Article  CAS  PubMed  Google Scholar 

  16. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene. 2006;25(11):1639–48.

    Article  CAS  PubMed  Google Scholar 

  17. Ginsberg G, Smolenski S, Hattis D, Guyton KZ, Johns DO, Sonawane B. Genetic Polymorphism in Glutathione Transferases (GST): Population distribution of GSTM1, T1, and P1 conjugating activity. J Toxicol Environ Health B Crit Rev. 2009;12(5–6):389–439.

    Article  CAS  PubMed  Google Scholar 

  18. Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 2012;118(9):2466–75.

    Article  CAS  PubMed  Google Scholar 

  19. Khrunin A, Ivanova F, Moisseev A, Khokhrin D, Sleptsova Y, Gorbunova V, et al. Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics. 2012;13(2):171–8.

    Article  CAS  PubMed  Google Scholar 

  20. Saip R, Sen F, Vural B, Ugurel E, Demirkan A, Derin D, et al. Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients. J BUON. 2011;16(2):241–6.

    CAS  PubMed  Google Scholar 

  21. Yang LM, Li XH, Bao CF. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors. Asian Pac J Cancer Prev. 2012;13(11):5883–6.

    Article  PubMed  Google Scholar 

  22. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenom J. 2010;10(1):54–61.

    Article  CAS  Google Scholar 

  23. Ke HG, Li J, Shen Y, You QS, Yan Y, Dong HX, et al. Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients. Asian Pac J Cancer Prev. 2012;13(9):4413–6.

    Article  PubMed  Google Scholar 

  24. Safaei R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett. 2006;234(1):34–9.

    Article  CAS  PubMed  Google Scholar 

  25. Arnesano F, Scintilla S, Natile G. Interaction between platinum complexes and a methionine motif found in copper transport proteins. Angew Chem Int Ed Engl. 2007;46(47):9062–4.

    Article  CAS  PubMed  Google Scholar 

  26. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev. 2007;26(1):71–83.

    Article  CAS  PubMed  Google Scholar 

  27. Tadini-Buoninsegni F, Bartolommei G, Moncelli MR, Inesi G, Galliani A, Sinisi M, et al. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B. Angew Chem Int Ed Engl. 2014;53(5):1297–301.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Gu YH, Kodama H, Murata Y, Mochizuki D, Yanagawa Y, Ushijima H, et al. ATP7A gene mutations in 16 patients with Menkes disease and a patient with occipital horn syndrome. Am J Med Genet. 2001;99(3):217–22.

    Article  CAS  PubMed  Google Scholar 

  29. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect. 2003;111(15):1843–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res. 2007;13(10):2876–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work is supported by Fujian Provincial Maternal and Child Health Hospital Foundation (14-35).

Author information

Author notes

    Authors and Affiliations

    1. Department of Pharmacy, Fujian Provincial Maternal and Child Health Hospital, 18 Daoshan Road, Fuzhou, Fujian, China

      J.-H. Deng, J. Deng, D.-H. Shi & P.-G. Niu

    2. Department of Oncology, Fuzhou General Hospital of PLA, Fuzhou, Fujian, China

      X.-N. Ouyang

    Authors
    1. J.-H. Deng
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. J. Deng
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. D.-H. Shi
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. X.-N. Ouyang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. P.-G. Niu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to D.-H. Shi.

    Additional information

    J.-H. Deng and J. Deng contributed equally to the manuscript.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    Supplementary material 1 (DOC 92 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Deng, JH., Deng, J., Shi, DH. et al. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients. Clin Transl Oncol 17, 720–726 (2015). https://doi.org/10.1007/s12094-015-1299-6

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12094-015-1299-6

    Keywords

    Search

    Navigation